Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Local Institution - 001-801-G, Gallatin, Tennessee
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
NCT03193151
Recruiting
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Vanderbilt University Medical Center, Vanderbilt Transplant Center, Nashville, Tennessee
Conditions: Liver Dysfunction
Register for Updates
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Intracranial Meningioma, Grade 2 Meningioma
Register for Updates
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
NCT06631287
Recruiting
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2025
Locations: Vanderbilt University Medical, Nashville, Tennessee
Conditions: Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT05691491
Recruiting
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2025
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: New Phase Research and Development, Knoxville, Tennessee
Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)
Register for Updates
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635
Recruiting
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: SCRI Oncology Partners ( Site 7000), Nashville, Tennessee
Conditions: Breast Neoplasms, Breast Cancer
Register for Updates
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06390319
Recruiting
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end o... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
07/11/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067
Recruiting
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in partic... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/11/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Memphis, Tennessee
Conditions: Major Depressive Disorder
Register for Updates
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Register for Updates